News
Moderna stock is indeed in the doldrums today, but this offers the opportunity to buy at a reasonable price, and, 10 years ...
The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...
The new results helped boost Moderna’s stock by more than 4% in early trading Monday, though the company’s shares are still ...
We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.
The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.
Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...
The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...
Moderna Inc. said its experimental flu shot met its goal in a late-stage trial, clearing the path for its broader strategy of ...
A top official at the Food and Drug Administration recently overruled government scientists on the availability of two ...
RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results